Health Care · Pharmaceutical Preparations · Nasdaq · CIK 875320 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $483.33Day −1.44%Mkt cap $122.7BP/E (FY) 31.5×1Y +3.2%Off 52W high −9.1%Vol (1Y) 35.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 6,679 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest2.0% of sh out |
| Days to cover3.1d |
| 13F net flow (QoQ)−0.16% |
| Top-10 13F concentration54.4% |
| Next report (est.)2026-08-03 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)31.5× |
| Sales (TTM)$12.22B |
| Earnings (TTM)$4.34B |
| ROE22.5% |
| Net margin32.9% |
| ROIC28.0% |
| EPS growth 3Y6.1% |
| Sales growth 3Y10.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+6.6% |
| 1Y+3.2% |
| 3Y+37.2% |
| 5Y+141.2% |
| 10Y+398.3% |
| Since incept. (ann.)+13.0% |
Total return through 2026-07-29 · series begins 2000-01-03. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)35.0% |
| Ann. volatility (3Y)29.5% |
| Sharpe (1Y)0.32 |
| Sharpe (3Y)0.51 |
| Max drawdown (1Y)−22.4% |
| Max drawdown (3Y)−29.1% |
| Beta (3Y vs SPY)0.14 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Capital World Investors | 25.4M | $11.3B | 9.99% | −0.6% |
| BlackRock, Inc. | 24.0M | $10.7B | 9.44% | +0.9% |
| Capital Research Global Investors | 21.1M | $9.4B | 8.32% | +22.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.5M | $7.4B | 6.50% | new |
| STATE STREET CORP | 11.7M | $5.2B | 4.62% | +0.3% |
| JPMORGAN CHASE & CO | 7.0M | $3.1B | 2.77% | +16.5% |
| GEODE CAPITAL MANAGEMENT, LLC | 6.1M | $2.7B | 2.42% | +2.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.1M | $2.3B | 2.03% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-04 | $4.02 | +61.4% | $2.99B | +7.8% |
| 2025-12-31 | 2026-02-12 | — | — | $3.19B | +9.5% |
| 2025-09-30 | 2025-11-03 | $4.20 | +4.7% | $3.08B | +11.0% |
| 2025-06-30 | 2025-08-04 | $3.99 | — | $2.96B | +12.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-03 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
Pharmaceuticals 100%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
